GlassScriptPhysician profile
Gauri J Kiefer
NPI 1780655829
$497.68
in general payments reported to CMS, 2019-2025
11 companies · $82.32 in 2025
The $82.32 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.47 · 2021: $136 · 2023: $112 · 2024: $80.30 · 2025: $82.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.25 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $203.56 | 2023-2025 | Tagrisso, Imfinzi, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2021 | |
| Exelixis INC. | $41.14 | 2024 | Cabometyx |
| Janssen Biotech, INC. | $39.23 | 2019 | |
| Clovis Oncology, INC. | $24.51 | 2019 | |
| Genentech USA, INC. | $22.73 | 2019 | |
| Amgen INC. | $15.41 | 2023 | Kyprolis |
| Tempus Ai, INC | $14.63 | 2024 | |
| Kite Pharma, INC. | $13.58 | 2021 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gauri Kiefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.